wayground logo

Free Printable Worksheets

NEW

Font size

S
M
L
XL
Worksheets

Ozempic® novoCare Multan Team Training (27 Sep 2021)

Total questions: 25

Worksheet time: 13mins

Name
Class
Date
1.

Glucose dependant secretion of insulin in response to nutrient intake is called

a)

GLP1

b)

Incretin effect

c)

GIP

d)

All of above

2.

GLP1 mediates it’s effects via receptors belonging to.........these receptors are found in pancreatic islets and also various other tissues throughout the body including brain, kidney, liver

a)

GLP Protein-coupled receptor family

b)

GIP Protein-coupled receptor family

c)

G Protein-coupled receptor family

d)

Both A & B

3.

Incretin based therapies include

a)

DPP4 & GLP1

b)

Only GLP1 RA

c)

Wish I knew!

4.

Semaglutide is a .....................GLP1 with ................. homology To native GLP1 hormone

a)

Human GLP-1 analogue, 94%

b)

GLP-1 Receptor agonist, 94%

c)

Human GLP-1 analogue, 97%

d)

Both A & B are correct

5.

GLP1 stands for

a)

Good laboratory practice

b)

Glucagon like peptide

c)

Guaranteed low price

d)

Glycogen like peptide

6.

An optimal diabetes therapy would provide improved glycemic control with minimal risk of hypoglycaemia, improve beta cell function & target other associated pathological defects of T2DM such as ........... , ............ & ..............

a)

Depression, Anxiety & Psychosis

b)

Obesity, Hypertension & Dyslipidaemia

c)

Osteoporosis, Cancer & Appendicitis

d)

I don’t know

7.

GLP1 is a natural incretin hormone secreted by ................ in response to food intake

a)

Stomach

b)

Pancreas

c)

Kidneys

d)

Intestine

8.

GLP1 stimulates insulin secretion & suppresses glucagon secretion but only when glucose levels are elevated thus protecting against hypoglycaemia

a)

True

b)

False

c)

I don’t know

9.

GLP1 delays stomach emptying and reduces appetite resulting in satiety (feeling of fullness) and contributing to weight loss

a)

True

b)

False

c)

I don’t know

10.

Native GLP1 has limited potential as a treatment for type 2 diabetes as it is rapidly degraded by enzyme ............ resulting in a half life of approx...............

a)

DNA polymerase, 3 min

b)

DNA polymerase, 1.5 minS

c)

DPP-4, 3 mins

d)

DPP-4, 1.5 mins

11.

GLP1 based therapies with .......... have been developed to clinically benefit from the positive effects of GLP1 receptor activation

a)

Short half life

b)

Long half life

c)

I don’t know

12.

Multiple physiological effects of GLP1 RA, makes it an attractive Type 2 Diabetes therapy.

a)

Agreed

b)

Disagreed

c)

I don’t care

d)

Strongly Agreed

13.

ADA/EASD guidelines recommends GLP1 RA as the ...................... injectable after metformin & before initiating ......................

a)

Second, Insulins

b)

Second, DPP4i

c)

First, Insulins

d)

First, DPP4

14.

GLP1 RAs reduce cardiovascular risk by modifying progression of atherosclerosis (the build up of fatty deposits in the arteries)

a)

True

b)

False

c)

I don’t care (Neutral)

15.

GLP1 RAs are recommended by guidelines in ................. patients with ASCVD (Atherosclerotic cardiovascular disease)

a)

Overweight

b)

Type 1 diabetic

c)

Type 2 diabetic

d)

All of above

16.

Modifications to native GLP1 molecule makes Semaglutide increases its albumin affinity and stability against metabolic degradation by DPP-4 giving it a half life of Approx............... making it suitable for ..................administration

a)

7 days, Once weekly

b)

5 days, Once weekly

c)

13 hours, Once weekly

d)

9 hours, Twice daily

17.

Ozempic (Semaglutide) is administered subcutaneously (abdomen, thigh or upper arm), once weekly (OW) on the same day each week, at any time of the day with or without meals

a)

True

b)

False

18.

Ozempic (Semaglutide) will be available in Pakistan as:

a)

Two Pre-Filled pens (DUAL Pen & 1 mg pen)

b)

Three Pre-Filled pens (0.25 mg, 0.5 mg & 1mg)

c)

Wish I knew!

19.

Ozempic (Semaglutide) is the most effective once weekly GLP-1 RA treatment for Type 2 Diabetes

a)

Absolutely

b)

Hope so

c)

Will find out

d)

Wish I Knew!

20.

No significant drug–drug interactions were observed when semaglutide was administered concomitantly with oral contraceptives, metformin, warfarin, atorvastatin and digoxin?

a)

TRUE

b)

FALSE

21.

What are the effects of semaglutide on appetite, energy intake and weight loss?

a)

Lowered energy intake and energy expenditure

b)

Corresponding reduction in body weight

c)

loss of appetite & food cravings

d)

ALL of the above

22.

Semaglutide exposure was not affected by hepatic or renal impairment in patients with T2D; therefore, it may be suitable for such patients without the need for dose adjustment.

a)

TRUE

b)

FALSE

23.

The SUSTAIN programme covers all aspects of the T2D patient care continuum, including ----- ---?

a)

Drug naive patients

b)

On OAD therapies at baseline

c)

With basal insulin

d)

All of above

24.

Does semaglutide pass the blood–brain barrier?

a)

TRUE

b)

FALSE

25.

Semaglutide worsened several aspects of beta-cell function vs placebo in subjects with T2D after 12 weeks of treatment. TRUE OR FALSE

a)

TRUE

b)

FALSE